Resonance tests FerriScan
Tuesday, 01 July, 2008
WA-based diagnostics company Resonance Health (ASX: RHT) has lodged an application with the Australian Medical Services Advisory Committee seeking reimbursement for its FerriScan iron test in Australia.
The company has already had some public funding success overseas, with the Whittington Hospital in London receiving funding approval from the British National Health Service [NHS].
FerriScan is used in to test for and measure levels of iron overload in the liver, caused by regular blood transfusions received by patients with sickle cell disease, thalassemia major and myelodysplastic syndromes.
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
